Victory Capital Management
SPHS

Victory Capital Management’s Sophiris Bio, Inc. SPHS Stock Holding History

Victory Capital Management’s Portfolio SPHS Stock Details SPHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-5,073
Closed -$3K – 3811
2019
Q3 		$3K Buy
+5,073
New +$4.51K ﹤0.01% 3607

Other funds holding SPHS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Victory Capital Management's SPHS Position: Q4 2019 in Review

Victory Capital Management sold out of Sophiris Bio, Inc. (SPHS) in Q4 2019, closing a stake of 5,073 shares — an estimated $3K sold.

Victory Capital Management first reported a position in SPHS in Q3 2019 and held it in 1 quarter. The position peaked at $3K in Q3 2019. 27 funds tracked by Wall St. Rank hold SPHS as of Q4 2019.

  • Victory Capital Management reported no remaining Sophiris Bio, Inc. position as of Q4 2019 after selling out during the quarter.
  • Victory Capital Management sold 5,073 Sophiris Bio, Inc. shares in Q4 2019, an estimated $3K.
  • Victory Capital Management first reported a position in Sophiris Bio, Inc. in Q3 2019 and held it in 1 quarter.
  • Victory Capital Management's Sophiris Bio, Inc. position peaked at $3K in Q3 2019.
  • 27 funds tracked by Wall St. Rank held Sophiris Bio, Inc. as of Q4 2019.

Based on Victory Capital Management's 13F filing for Q4 2019, filed 4 Feb 2020.